Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«123456»
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Frequency of virologic factors possibly associated with CAB/RPV LAI failure () -  May 12, 2022 - Abstract #AIDS2022AIDS_850;    
    Despite common presence of factors associated with CAB/RPV failure they rarely occurred in combination. Defining subtype and screening for INSTI and NNRTI mutations should be performed prior to LAI treatment implementation.
  • ||||||||||  Vocabria (cabotegravir oral) / ViiV Healthcare
    'Give it a Shot': best practices from HCPs for administering long-acting cabotegravir+rilpivirine () -  May 12, 2022 - Abstract #AIDS2022AIDS_779;    
    In the Phase 3/3b studies, CAB+RPV LA injections were well tolerated, associated with low rates of treatment discontinuation due to injection site reactions, and preferred by patients over daily oral therapy. These data support that simple techniques, routinely used by injectors, help optimize the administration of CAB+RPV LA.
  • ||||||||||  Apretude (cabotegravir extended-release injectable suspension) / ViiV Healthcare, lenacapavir (GS CA2) / Gilead, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Journal:  Implementation of long-acting antiretroviral therapy in low-income and middle-income countries. (Pubmed Central) -  Apr 26, 2022   
    However, there are multiple implementation considerations in LMICs including the need for exclusion of hepatitis B, cold chain, oral bridging in case of missed dosing and switching during tuberculosis therapy. Efficacy and safety data are also awaited for settings without routine access to baseline resistance testing or regular viral load monitoring and for special populations, such as pregnancy, children and the elderly.
  • ||||||||||  Apretude (cabotegravir extended-release injectable suspension) / ViiV Healthcare, lenacapavir (GS CA2) / Gilead, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Journal:  Implementation of long-acting antiretroviral therapy in low-income and middle-income countries. (Pubmed Central) -  Apr 20, 2022   
    However, there are multiple implementation considerations in LMICs including the need for exclusion of hepatitis B, cold chain, oral bridging in case of missed dosing and switching during tuberculosis therapy. Efficacy and safety data are also awaited for settings without routine access to baseline resistance testing or regular viral load monitoring and for special populations, such as pregnancy, children and the elderly.
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Will I gain weight on cabenuva 😟 (Twitter) -  Apr 10, 2022   
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Enrollment open:  Implementing Cabenuva in Arkansas HIV Programs (clinicaltrials.gov) -  Mar 22, 2022   
    P=N/A,  N=100, Recruiting, 
    Most participants preferred CAB+RPV long-acting to their prior oral CAB+RPV regimen at M12. Not yet recruiting --> Recruiting
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Enrollment open, Adherence:  I-TRAINS: Improving Treatment and Retention Adherence in Nontraditional Settings (clinicaltrials.gov) -  Mar 11, 2022   
    P=N/A,  N=60, Enrolling by invitation, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Enrolling by invitation
  • ||||||||||  Vocabria (cabotegravir oral) / ViiV Healthcare, Apretude (cabotegravir extended-release injectable suspension) / ViiV Healthcare
    Journal:  Cabotegravir (Apretude) for HIV-1 pre-exposure prophylaxis. (Pubmed Central) -  Feb 23, 2022   
    Not yet recruiting --> Enrolling by invitation No abstract available
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Enrollment open, Trial completion date, Trial primary completion date:  GLACIER: Study Using CABENUVA (clinicaltrials.gov) -  Feb 17, 2022   
    P4,  N=120, Recruiting, 
    No abstract available Not yet recruiting --> Recruiting | Trial completion date: Feb 2023 --> Oct 2023 | Trial primary completion date: Feb 2023 --> Oct 2023
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    TRANSFORMATION OF DOLUTEGRAVIR INTO A YEAR-LONG PARENTERAL PRODRUG FORMULATION ([VIRTUAL]) -  Feb 7, 2022 - Abstract #CROI2022CROI_622;    
    The extended NM2DTG PK profile paralleled nanocrystal dissolution and pH-dependent prodrug activation. NM2DTG produced plasma DTG levels at or above the PA-IC90 for one year following a single intramuscular injection in rodents.
  • ||||||||||  Vocabria (cabotegravir oral) / ViiV Healthcare
    EFFECT OF L74I POLYMORPHISM ON FITNESS OF HIV-1 SUBTYPE A6 RESISTANT TO CABOTEGRAVIR ([VIRTUAL]) -  Feb 7, 2022 - Abstract #CROI2022CROI_554;    
    Presence of the L74I polymorphism conferred greater replication capacity to recombinant viruses expressing HIV-1 A6 IN when present together with INSTI resistance mutations at positions 118, 140, 148 and 263. This finding may explain, in part, the association of HIV-1 subtype A6 and virologic failure observed in clinical trials of CAB-LA in combination with RPV-LA.
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Phase classification, Trial completion date, Trial primary completion date:  Implementing Cabenuva in Arkansas HIV Programs (clinicaltrials.gov) -  Feb 2, 2022   
    P=N/A,  N=100, Not yet recruiting, 
    This finding may explain, in part, the association of HIV-1 subtype A6 and virologic failure observed in clinical trials of CAB-LA in combination with RPV-LA. Phase classification: P1 --> P=N/A | Trial completion date: Nov 2022 --> Feb 2023 | Trial primary completion date: Nov 2022 --> Feb 2023
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Phase classification, Enrollment change, Trial initiation date, Adherence:  I-TRAINS: Improving Treatment and Retention Adherence in Nontraditional Settings (clinicaltrials.gov) -  Jan 26, 2022   
    P=N/A,  N=60, Not yet recruiting, 
    Phase classification: P1 --> P=N/A | Trial completion date: Nov 2022 --> Feb 2023 | Trial primary completion date: Nov 2022 --> Feb 2023 Phase classification: P4 --> P=N/A | N=100 --> 60 | Initiation date: Dec 2022 --> Feb 2022
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Long Acting Antiretroviral Therapy for the Treatment and Prevention of HIV Infection ([VIRTUAL]) -  Dec 2, 2021 - Abstract #ASHP2021ASHP_4748;    
    As novel antiretrovirals with unique delivery systems, the long-acting injections cabotegravir and rilpivirine will provide the first alternative option to daily oral medication for treating and preventing HIV...Recommend strategies for solving drug therapy related problems common to long-acting antiretroviral agents including missed doses, adverse drug reactions and drug–drug interactions. Target Audience: Pharmacist Level of Content:Advanced
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Trial initiation date, Adherence:  I-TRAINS: Improving Treatment and Retention Adherence in Nontraditional Settings (clinicaltrials.gov) -  Nov 30, 2021   
    P4,  N=100, Not yet recruiting, 
    Target Audience: Pharmacist Level of Content:Advanced Initiation date: Nov 2021 --> Dec 2022
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Phase classification:  Implementing Cabenuva in Arkansas HIV Programs (clinicaltrials.gov) -  Nov 18, 2021   
    P1,  N=100, Not yet recruiting, 
    Initiation date: Nov 2021 --> Dec 2022 Phase classification: P=N/A --> P1
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Trial completion date, Trial initiation date, Trial primary completion date:  Cabenuva Injection Tracking in CHORUS (clinicaltrials.gov) -  Oct 29, 2021   
    P=N/A,  N=43, Enrolling by invitation, 
    Phase classification: P=N/A --> P1 Trial completion date: Mar 2022 --> Jul 2022 | Initiation date: Apr 2021 --> Oct 2021 | Trial primary completion date: Jan 2022 --> Jul 2022
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    New P1 trial, New trial:  Implementing Cabenuva in Arkansas HIV Programs (clinicaltrials.gov) -  Oct 27, 2021   
    P=N/A,  N=100, Not yet recruiting, 
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Review, Journal:  Design strategies for long-acting anti-HIV pharmaceuticals. (Pubmed Central) -  Oct 13, 2021   
    The clinical phase III trials of FLAIR and ATLAS, showed two-drug injectable cabotegravir (CAB) and rilpivirine (RPV) formulation is potent, safe, and tolerable in HIV-infected patients...Broadly neutralizing antibodies (bNAbs) with excellent breath and efficiency against HIV have been investigated as LA antiviral weapons. Several modern modalities capable of sustained drug release for long-term treatment and prevention of HIV infection are also in development, such as implants, vaginal rings, and nanotherapies.
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    [VIRTUAL] Implementation of Long-acting Injectable Cabotegravir/Rilpivirine for HIV-1 Treatment at a Ryan White-funded Clinic in the U.S. South () -  Oct 6, 2021 - Abstract #IDWeek2021IDWeek_1795;    
    Our experience implementing LAI-ART at a Ryan White-funded HIV clinic in the Southern U.S. has been challenged by substantial human resource capital to attain drug, delayed therapy initiation due to insurance denials, and patient ineligibility primarily due to concern for potential RPV resistance. These barriers may perpetuate disparities in ART access and virologic suppression among PWH and need to be urgently addressed so that LAI-ART can be offered equitably.